| Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Where are we going |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Where we stand |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Parsing the Paradox of Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncologysd |
Myelodysplastic Syndromes (MDS) |
| Pathogenesis of paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
|
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
